嵌合抗原受体
医学
淋巴瘤
耐火材料(行星科学)
细胞疗法
癌症研究
抗原
肿瘤科
免疫学
免疫疗法
细胞
生物
免疫系统
遗传学
天体生物学
作者
Raúl del Toro-Mijares,Olalekan O. Oluwole,Reena Jayani,Adetola A. Kassim,Bipin N. Savani,Bhagirathbhai Dholaria
摘要
Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after failure of chemoimmunotherapy. However, patients who are refractory or relapsing after CAR-T therapy have poor outcomes. Multiple mechanisms of CAR-T therapy failure have been proposed but management of these patients remains a challenge. As CAR-T therapy moves earlier in the treatment of DLBCL, we urgently need trials focused on patients with relapse after CAR-T therapy. Recent advances in novel immunotherapies such as bispecific antibodies, antibody-drug conjugates and next-generation CAR-T therapies may provide avenues for treatment. Here we review the available data on using these drugs after failure of CAR-T therapy and provide a framework for the ideal sequencing of these novel agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI